Referenser

  1. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015;30(12):1591-601.

  2. Ben-Shlomo Y, Darweesh S, Llibre-Guerra J, Marras C, San Luciano M, Tanner C. The epidemiology of Parkinson's disease. Lancet. 2024;403(10423):283-92.

  3. Bologna M, Truong D, Jankovic J. The etiopathogenetic and pathophysiological spectrum of parkinsonism. J Neurol Sci. 2022;433:120012.

  4. Morris HR, Spillantini MG, Sue CM, Williams-Gray CH. The pathogenesis of Parkinson's disease. Lancet. 2024;403(10423):293-304.

  5. Puschmann A, Jiménez-Ferrer I, Lundblad-Andersson E, Mårtensson E, Hansson O, Odin P, et al. Low prevalence of known pathogenic mutations in dominant PD genes: A Swedish multicenter study. Parkinsonism Relat Disord. 2019;66:158-65.

  6. Chen Z, Li G, Liu J. Autonomic dysfunction in Parkinson's disease: Implications for pathophysiology, diagnosis, and treatment. Neurobiol Dis. 2020;134:104700.

  7. SWEMODIS. Svenska riktlinjer för utredning och behandling av Parkinsons sjukdom. Version #9 2022. Available from: https://www.swemodis.se/Behandlingsriktlinjer/

  8. Macleod AD, Henery R, Nwajiugo PC, Scott NW, Caslake R, Counsell CE. Age-related selection bias in Parkinson's disease research: are we recruiting the right participants? Parkinsonism Relat Disord. 2018;55:128-33.

  9. Espay AJ, Morgante F, Merola A, Fasano A, Marsili L, Fox SH, et al. Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts. Ann Neurol. 2018;84(6):797-811.

  10. Tran TN, Vo TNN, Frei K, Truong DD. Levodopa-induced dyskinesia: clinical features, incidence, and risk factors. J Neural Transm (Vienna). 2018;125(8):1109-17.

  11. Hung SW, Adeli GM, Arenovich T, Fox SH, Lang AE. Patient perception of dyskinesia in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2010;81(10):1112-5.

  12. Ahlskog JE. Parkinson's disease progression is multifaceted: Evidence for the underlying benchmarks. Parkinsonism Relat Disord. 2024;121:106037.

  13. Warren N, O'Gorman C, Lehn A, Siskind D. Dopamine dysregulation syndrome in Parkinson's disease: a systematic review of published cases. J Neurol Neurosurg Psychiatry. 2017;88(12):1060-4.

  14. Debove I, Paschen S, Amstutz D, Cardoso F, Corvol JC, Fung VSC, et al. Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus. Mov Disord. 2024;39(2):235-48.

  15. Yu XX, Fernandez HH. Dopamine agonist withdrawal syndrome: A comprehensive review. J Neurol Sci. 2017;374:53-5.

  16. Pagonabarraga J, Bejr-Kasem H, Martinez-Horta S, Kulisevsky J. Parkinson disease psychosis: from phenomenology to neurobiological mechanisms. Nat Rev Neurol. 2024;20(3):135-50.

  17. Nilsson M, Franzén E, Winberg C. Svenska riktlinjer för fysioterapi vid Parkinsons sjukdom. 2018. Available from: https://www.swemodis.se/Behandlingsriktlinjer/

  18. Groves MS, Forrest DV. Parkinson's disease as a model for psychosocial issues in chronic neurodegenerative disease. Adv Neurol. 2005;96:65-83.

Föregående sida
För vidare läsning

Nästa sida
Tillbaka till kapitlets första sida